Cristina de Castro Spadari
Overview
Explore the profile of Cristina de Castro Spadari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodrigues C, Bento C, Moraes C, Gomes C, Ioshino R, Freitas-Junior L, et al.
Fitoterapia
. 2024 Jan;
173:105820.
PMID: 38211642
In this study, we specifically focused on the crude methanolic leaf extract of Byrsonima coccolobifolia, investigating its antifungal potential against human pathogenic fungi and its antiviral activity against COVID-19. Through...
2.
de Castro Spadari C, Borba-Santos L, Rozental S, Ishida K
J Mycol Med
. 2023 Sep;
33(4):101436.
PMID: 37774486
Fungal infections are a global health problem with high mortality and morbidity rates. Available antifungal agents have high toxicity and pharmacodynamic and pharmacokinetic limitations. Moreover, the increased incidence of antifungal-resistant...
3.
Santos-Lima D, de Castro Spadari C, de Morais Barroso V, Carvalho J, de Almeida L, Alcalde F, et al.
Appl Microbiol Biotechnol
. 2023 Aug;
107(19):6103-6120.
PMID: 37561179
Bacillus subtilis species complex is known as lipopeptide-producer with biotechnological potential for pharmaceutical developments. This study aimed to identify lipopeptides from a bacterial isolate and evaluate their antifungal effects. Here,...
4.
De Jesus D, De Freitas A, De Oliveira I, de Almeida L, Bastos R, de Castro Spadari C, et al.
Antimicrob Agents Chemother
. 2023 Feb;
67(3):e0075922.
PMID: 36815840
Cryptococcosis therapy is often limited by toxicity problems, antifungal tolerance, and high costs. Studies approaching chalcogen compounds, especially those containing selenium, have shown promising antifungal activity against pathogenic species. This...
5.
Sannomiya M, Rodrigues C, Oliveira G, Carvalho J, da Costa L, de Castro Spadari C, et al.
J Ethnopharmacol
. 2022 Jul;
297:115534.
PMID: 35842178
Ethnopharmacological Relevance: Byrsonima fagifolia Niedenzu (Malpighiaceae) and other Byrsonima species are popularly employed in Brazilian traditional medicine in the form of preparations as cicatrizing, anti-inflammatory, and antimicrobial. Aim Of The...
6.
de Castro Spadari C, Barreto T, Tebaldi de Queiroz V, de Paiva W, Antonio Fernandes S, de Fatima A, et al.
J Mycol Med
. 2022 Feb;
32(2):101254.
PMID: 35168160
Ketoconazole (KTZ) is an antifungal agent; however, its bioavailability and therapeutic efficacy are reduced by the low aqueous solubility of the drug. Aiming at providing to improve the biopharmaceutical properties...
7.
de Castro Spadari C, Wirth F, Lopes L, Ishida K
Microorganisms
. 2020 Apr;
8(4).
PMID: 32340403
Cryptococcosis is an important opportunistic infection and a leading cause of meningitis in patients with HIV infection. The antifungal pharmacological treatment is limited to amphotericin B, fluconazole and 5- flucytosine....
8.
de Bastiani F, de Castro Spadari C, de Matos J, Cassone Salata G, Lopes L, Ishida K
Front Microbiol
. 2020 Jan;
10:2976.
PMID: 31998264
Topical drug administration is frequently used for the treatment of vaginal candidiasis; however, most formulations using this route do not provide prolonged drug release. Our aim was to evaluate the...
9.
de Castro Spadari C, de Bastiani F, Pisani P, Melo A, Ishida K
Arch Microbiol
. 2019 Dec;
202(4):773-784.
PMID: 31832690
Cryptococcosis is a common opportunistic infection in patients with advanced HIV infection and may also affect immunocompetent patients. The available antifungal agents are few and other options are needed for...
10.
de Castro Spadari C, de Bastiani F, Lopes L, Ishida K
Int J Nanomedicine
. 2019 Aug;
14:5187-5199.
PMID: 31371955
Introduction And Objective: Previous studies indicate that miltefosine (MFS) may be an alternative as an antifungal agent; however, it presents several adverse effects. Thus, the aim of this study was...